FINWIRES · TerminalLIVE
FINWIRES

Clarity Pharmaceuticals to Start Registrational Phase 3 Trial in Neuroendocrine Tumors After US FDA Meeting

By

Clarity Pharmaceuticals (ASX:CU6) will start a registrational phase 3 trial of copper-64-SARTATE in neuroendocrine tumors, following a successful end-of-phase meeting with the US Food and Drug Administration (FDA), according to a Thursday Australian bourse filing.

The company plans to recruit around 70 participants for the trial.

Clarity is also conducting recruitment for its registrational phase 3 positron emission tomography imaging trial of participants with high-risk prostate cancer prior to radical prostatectomy using copper-64-SAR-bisPSMA in the US and Australia, per the filing. It plans to recruit around 383 participants.

The trial will assess the diagnostic performance of copper-64-SAR-bisPSMA positron emission tomography in detecting prostate cancer within the pelvic lymph nodes, the filing said.

Clarity Pharmaceuticals' shares fell nearly 2% in recent trading on Thursday.

Related Articles

Asia

Joinn Laboratories' Profit Surges 480% in Q1

Joinn Laboratories (HKG:6127, SHA:603127) posted net profit attributable to shareholders of 238.4 million yuan for the first quarter, up 480% from 41.1 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.Hong Kong-listed shares of the drug research firm were down over 6% in Thursday's late-morning trade.Earnings per share came in at 0.32 yuan, up from 0.05 yuan a year earlier.Revenue increased 10% to 316.1 million yuan from 287.3 million yuan in the prior-year period.

HKG:6127SHA:603127
Asia

Ganfeng Lithium Turns to Q1 Profit as Revenue Jumps 144%

Ganfeng Lithium (SHE:002460, HKG:1772) posted first-quarter attributable net profit of 1.84 billion yuan, compared with loss of 355.8 million yuan the previous year.Earnings per share stood at 0.88 yuan, versus loss per share of 0.18 yuan last year, according to a Thursday filing with the Shenzhen bourse.Operating revenue jumped 144% year over year to 9.20 billion yuan from 3.77 billion yuan.Shares of the lithium miner were up 2% in recent trade on the Shenzhen bourse and 1% on the Hong Kong bourse.

HKG:1772SHE:002460
Asia

Yihai Kerry Arawana Q1 Profit Up 51%, Revenue Rises 11%

Yihai Kerry Arawana (SHE:300999) posted first-quarter attributable net profit of 1.48 billion yuan, up 51% from 981.4 million yuan the previous year.Earnings per share rose to 0.27 yuan from 0.18 yuan, according to a Thursday filing with the Shenzhen bourse.Operating revenue climbed 11% year over year to 65.5 billion yuan from 59.1 billion yuan.Shares of the food products company were up 2% in recent trade.

SHE:300999